Cantor Fitzgerald Comments on Bioventus FY2025 Earnings

Bioventus Inc. (NYSE:BVS - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Bioventus in a report released on Thursday, August 7th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will earn $0.30 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $12.00 price objective on the stock. The consensus estimate for Bioventus' current full-year earnings is $0.41 per share. Cantor Fitzgerald also issued estimates for Bioventus' FY2026 earnings at $0.51 EPS.

Separately, Craig Hallum set a $15.00 price objective on shares of Bioventus and gave the company a "buy" rating in a research note on Wednesday, May 7th.

Bioventus Trading Down 2.2%

Bioventus stock traded down $0.17 during midday trading on Monday, reaching $7.37. The stock had a trading volume of 283,172 shares, compared to its average volume of 396,201. The firm has a market cap of $604.99 million, a price-to-earnings ratio of -12.05 and a beta of 0.83. The company has a fifty day moving average of $6.71 and a 200 day moving average of $7.96. Bioventus has a 52-week low of $5.81 and a 52-week high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Institutional Investors Weigh In On Bioventus

Hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company's stock valued at $211,000 after purchasing an additional 1,538 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Bioventus by 106.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock valued at $36,000 after purchasing an additional 1,786 shares during the period. EP Wealth Advisors LLC raised its position in Bioventus by 17.0% during the fourth quarter. EP Wealth Advisors LLC now owns 14,096 shares of the company's stock worth $148,000 after acquiring an additional 2,047 shares during the last quarter. EntryPoint Capital LLC raised its position in Bioventus by 7.8% during the first quarter. EntryPoint Capital LLC now owns 28,371 shares of the company's stock worth $260,000 after acquiring an additional 2,048 shares during the last quarter. Finally, Summit Global Investments grew its holdings in shares of Bioventus by 3.9% during the first quarter. Summit Global Investments now owns 54,752 shares of the company's stock worth $501,000 after buying an additional 2,077 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.